驱动类风湿关节炎相关抗原选择性靶向局部补体抑制的双特异性抗体的研制
研究设计双特异性抗体(bsAb),一臂结合氨甲酰化蛋白等疾病相关抗原,另一臂招募内源性补体调节蛋白因子H(FH)或C4b结合蛋白(C4BP),以仅在局部抑制补体而保留全身补体功能。体外实验证实bsAb对氨甲酰化蛋白具有特异性,可有效招募FH或C4BP,并抑制免疫球蛋白G免疫复合物及类风湿关节炎患者抗氨甲酰化蛋白抗体触发的补体激活至背景水平。
要点
- 双特异性抗体一臂靶向氨甲酰化蛋白,另一臂招募FH或C4BP实现局部补体抑制。
- bsAb可抑制免疫球蛋白G免疫复合物诱导的补体激活。
- bsAb能将类风湿关节炎患者抗氨甲酰化蛋白抗体触发的补体激活抑制至背景水平。
核心结论
- 结合氨甲酰化蛋白与FH或C4BP的双特异性抗体可从血浆中特异性招募内源性补体调节蛋白,实现选择性局部靶向补体抑制,为自身免疫病的局部治疗提供新途径。
研究设计与样本
- 研究采用受控Fab臂交换技术设计双特异性抗体,一臂结合氨甲酰化蛋白等疾病相关抗原,另一臂招募内源性补体调节蛋白FH或C4BP。
- 随后对这些双特异性抗体的特异性和补体调节蛋白招募能力进行体外评价。
主要发现
- 成功生成基于抗氨甲酰化蛋白抗体的双特异性抗体,并确认其对氨甲酰化蛋白具有特异性。
- 双特异性抗体能有效将FH或C4BP招募至含氨甲酰化蛋白的表面。
- 双特异性抗体抑制了免疫球蛋白G免疫复合物诱导的补体激活。
- 双特异性抗体能将类风湿关节炎患者抗氨甲酰化蛋白抗体触发的补体激活抑制至背景水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In rheumatoid arthritis (RA) autoantibodies can trigger complement activation in the joint, contributing to tissue damage. Complement inhibitory drugs have shown important benefit in other clinical conditions. However, their use is limited because these drugs act systemically, not only requiring high doses but also rendering patients more susceptible to infections. Therefore, we designed a strategy to only inhibit complement locally, while leaving the systemic complement system intact to fight infections. METHODS: We designed bispecific antibodies (bsAbs) using controlled Fab-arm exchange. In these bsAbs, one antibody arm binds to a specific disease-relevant antigen, like carbamylated proteins, while the other arm recruits endogenous complement regulators, like factor H (FH) or C4b-binding protein (C4BP). These bsAbs were subsequently evaluated for their specificity and complement regulator recruiting capacity. RESULTS: We generated anti-carbamylated protein antibody (anti-CarP)-based bsAbs and confirmed specificity for carbamylated proteins. The bsAbs efficiently recruited FH or C4BP to surfaces containing carbamylated proteins. The bsAbs inhibited complement activation induced by immunoglobulin G immune complexes and more importantly, the bsAbs were able to inhibit complement activation triggered by anti-CarP antibodies from RA patients to background levels. CONCLUSIONS: This study shows that bsAbs that bind carbamylated proteins and FH or C4BP can specifically recruit the endogenous complement regulatory proteins from plasma to achieve selective local targeted complement inhibition, providing a new therapeutic approach for the local treatment of autoimmune diseases.
引用
- Wang H, Nugteren S, Groenland RJ, et al. Development of bispecific antibodies that drive selective targeted local complement inhibition on rheumatoid arthritis-related antigens. Ann Rheum Dis. 2025. PMID: 40683829. doi:10.1016/j.ard.2025.06.2130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。